Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials

被引：0
|
作者：
Michael Kreuter
Harald Koegler
Matthias Trampisch
Silke Geier
Luca Richeldi
机构：
[1] Pneumology and Respiratory Care Medicine,Center for Interstitial and Rare Lung Diseases
[2] Thoraxklinik,Università Cattolica del Sacro Cuore
[3] University of Heidelberg,undefined
[4] Boehringer Ingelheim International GmbH,undefined
[5] Fondazione Policlinico A. Gemelli,undefined
来源：
Respiratory Research | / 20卷
关键词：
Nintedanib; Tyrosine kinase inhibitor; Serious adverse events; Disease progression; Treatment outcome;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials
    Kreuter, Michael
    Koegler, Harald
    Trampisch, Matthias
    Geier, Silke
    Richeldi, Luca
    RESPIRATORY RESEARCH, 2019, 20 (1):
  • [2] Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis
    Collard, Harold R.
    Richeldi, Luca
    Kim, Dong Soon
    Taniguchi, Hiroyuki
    Tschoepe, Inga
    Luisetti, Maurizio
    Roman, Jesse
    Tino, Gregory
    Schlenker-Herceg, Rozsa
    Hallmann, Christoph
    du Bois, Roland M.
    EUROPEAN RESPIRATORY JOURNAL, 2017, 49 (05)
  • [3] EFFICACY OF NINTEDANIB ON ACUTE EXACERBATIONS REPORTED AS SERIOUS ADVERSE EVENTS IN THE INPULSIS® TRIALS IN IDIOPATHIC PULMONARY FIBROSIS (IPF)
    Richeldi, L.
    Koegler, H.
    Trampisch, M.
    Geier, S.
    Kreuter, M.
    THORAX, 2016, 71 : A58 - A59
  • [4] Efficacy Of Nintedanib On Acute Exacerbations Reported As Serious Adverse Events In The Inpulsis® Trials In Idiopathic Pulmonary Fibrosis (ipf)
    Kreuter, M.
    Koegler, H.
    Trampisch, M.
    Geier, S.
    Richeldi, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [5] The INPULSIS enigma: exacerbations in idiopathic pulmonary fibrosis
    Suissa, Samy
    Ernst, Pierre
    THORAX, 2015, 70 (05) : 508 - 510
  • [6] The INPULSIS trials of idiopathic pulmonary fibrosis treatment: explaining further discrepancies on exacerbations
    Suissa, Samy
    Ernst, Pierre
    EUROPEAN RESPIRATORY JOURNAL, 2016, 47 (01) : 344 - 345
  • [7] Effect Of Nintedanib On Disease Progression In The Inpulsis® Trials In Patients With Idiopathic Pulmonary Fibrosis (ipf)
    Raghu, G.
    Inoue, Y.
    Behr, J.
    Cottin, V.
    Stowasser, S.
    Stansen, W.
    Maher, T. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [8] POOLED ANALYSIS OF MORTALITY DATA FROM THE TOMORROW AND INPULSIS TRIALS OF NINTEDANIB IN IDIOPATHIC PULMONARY FIBROSIS (IPF)
    Corte, T.
    Richeldi, L.
    Kirsten, A.
    Roman, J.
    Le Maulf, F.
    Hallmann, C.
    Stowasser, S.
    Lasky, J.
    RESPIROLOGY, 2015, 20 : 87 - 87
  • [9] Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials
    Ulrich Costabel
    Jürgen Behr
    Bruno Crestani
    Wibke Stansen
    Rozsa Schlenker-Herceg
    Susanne Stowasser
    Ganesh Raghu
    Respiratory Research, 19
  • [10] Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials
    Costabel, Ulrich
    Behr, Juergen
    Crestani, Bruno
    Stansen, Wibke
    Schlenker-Herceg, Rozsa
    Stowasser, Susanne
    Raghu, Ganesh
    RESPIRATORY RESEARCH, 2018, 19
12345